BMS Australia has advised us that the abatacept subcutaneous (SC) presentations shortage has been resolved.
What this means is:
- The Serious Scarcity Substitution Instrument (SSSI) and the TGA shortage notification for the SC preparations of abatacept is no longer in place
- The Orencia Stock Hypercare Plan (OSHP) has ceased and normal prescribing and ordering processes for all abatacept presentations has resumed
- Patients may switch back to, and new patients may be initiated on, any of the abatacept presentations (IV or SC) as deemed appropriate by their treating physician
Please contact your treating specialist or rheumatology healthcare team if you have any further questions.